RxDoctor Payments Data

Theodore Conte, MD

Neurology · Paramus, NJNPI 1053366724

Payments from drug & device makers

$5,219in general payments, 2019–2025

Across 408 payments — averaging $12.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$432
  • Amgen$432
  • Lilly USA, LLC$428
  • Neurocrine Biosciences, Inc.$343
  • Kyowa Kirin, Inc.$288
  • plus $2K from 32 others

What the payments were for

  • Consulting fees$1753%
  • Food & beverage$5,04497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,219 in reported general payments places this provider in the 60th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$59,528
Medicare patients
103
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NourianzIstradefylline29$105,357
Nurtec OdtRimegepant Sulfate24$47,333
UbrelvyUbrogepant27$42,029
RexultiBrexpiprazole17$38,277
RytaryCarbidopa/Levodopa16$33,098
GocovriAmantadine Hcl17$31,931
NeuproRotigotine23$20,606
OngentysOpicapone22$19,263
Aimovig AutoinjectorErenumab-Aooe11$16,601
QuliptaAtogepant15$15,124
Emgality PenGalcanezumab-Gnlm12$13,960
Lidocaine36$11,422
HorizantGabapentin Enacarbil11$10,029
ReyvowLasmiditan Succinate13$8,945
Memantine Hcl79$4,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kyowa Kirin, Inc.Nourianz$288$105,35729 claims
AbbVieUbrelvy, Qulipta$1,235$57,15342 claims
PfizerNurtec Odt$14$47,33324 claims
Otsuka America Pharmaceutical, Inc.Rexulti$146$38,27717 claims
Amneal Pharmaceuticals LLCRytary$100$33,09816 claims
MDD US Operations, LLCGocovri$113$31,93117 claims
Neurocrine Biosciences, Inc.Ongentys$343$19,26322 claims
Arbor Pharmaceuticals, Inc.Horizant$19$10,02911 claims
Lilly USA, LLCReyvow$428$8,94513 claims
Upsher-smith Laboratories LLCTopiramate$76$54221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 521 neurology providers in New Jersey.

Other neurology in Paramus

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →